ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Health announces new packaging option now available in the U.S. for Dovato
PITTSBURGH and BANGALORE, India, Sept. 5, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients.
ViiV Healthcare`s Dovato (dolutegravir, lamivudine) Receives Approval in Europe
FDA Confirms Paragraph IV Patent Litigation for Abacavir Sulfate, Dolutegravir and Lamivudine Tablets
ViiV Healthcare`s Dovato (dolutegravir / lamivudine) Receives Approval in the Europe
FDA Confirms Paragraph IV Patent Litigation for Delstrigo (Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate)
Laurus Labs Generic Abacavir Sulfate Receives Approval in the U.S.
The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, ‘4-in-1’ fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV. This combination treatment has been developed by Cipla and the not-for-profit Drugs for Neglected Diseases initiative (DNDi).
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg